InterMune (NASDAQ: ITMN) today announced that patient enrollment has begun in ASCEND, a new Phase 3 study of pirfenidone for patients who suffer from idiopathic pulmonary fibrosis (IPF). ASCEND is a multinational, randomized, double-blind, placebo controlled Phase 3 trial designed to evaluate the safety and efficacy of Esbriet® (pirfenidone) in IPF patients with mild to moderate impairment in lung function. The primary endpoint is lung function, as measured by change in forced vital capacity (FVC) from baseline to Week 52. The trial will enroll a total of approximately 500 patientswho will be randomly assigned 1 to 1 to receive oral pirfenidone (2403 mg/day) or placebo. Patients will be enrolled at centers in the United States, Mexico, South America, Australia and New Zealand.

Just desire to say your article is as surprising. The clarity in your post is just excellent and i could assume you are an expert on this subject. Fine with your permission allow me to grab your RSS feed to keep updated with forthcoming post. Thanks a million and please carry on the rewarding work.